You just read:

Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jun 14, 2019, 07:30 ET